The rise in profits was attributed to the robust performance in international markets and growth in new launches from ...

Emcure's Poviztra weight loss brand thrives post-price cut, contributing to $1 billion revenue milestone for FY26.

Emcure Pharmaceuticals Ltd on Tuesday reported a 24 per cent increase in consolidated net profit at ₹243.74 crore in the ...

Reported Standalone quarterly numbers for Emcure Pharmaceuticals are: Net Sales at Rs 1,467.70 crore in March 2026 up 14.83% ...

Emcure Pharma posts 29% profit growth and 17% revenue rise in Q4FY26; stock falls over 5% after hitting a 52-week high of ...

Overseas sales outpace domestic growth; company scales injectables, biosimilars, expands in Europe, Canada ...

While the broader market remained positive, Emcure Pharma's stock moved in the opposite direction.

The new dosage variant is designed to provide a more effective and convenient option for patients with iron deficiency and iron deficiency anaemia (IDA). DCGI-approved FCM is indicated for the ...

The board has also recommended a final dividend of Rs 3.6 per fully paid-up equity share of Rs 10 each for the financial year ...

Namita Thapar simply loves her business. As Executive Director of the India business at Pune-based Emcure Pharmaceuticals, she barely pauses when you ask her what the vision for the company is. “We ...

Emcure Pharmaceuticals IPO subscription status: The initial public offering of Emcure Pharmaceuticals Ltd kickstarts for subscriptions today (Wednesday, July 3 ...

The company had posted a consolidated net profit of ₹197.24 crore in the corresponding quarter last fiscal, Emcure ...